RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Zynex (ZYXI – Research Report) on December 17 and set a price target of $11.00. The company’s shares closed yesterday at $8.17.
Zynex (ZYXI) announced a new partnership to conduct business with Veterans Affairs Medical Centers – VAMCs – across the U.S. It is estimated ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
ENGLEWOOD, Colo., Dec. 12, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company ...
ENGLEWOOD, Colo., Dec. 12, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) (“Zynex”, “ZMS”, “we” or the “Company”), an innovative medical technology ...
Zynex operates primarily in the pain management sector, with a strategic emphasis on profitable growth and sales representative productivity. The company's product portfolio includes devices for pain ...
Copyright 2024 The Associated Press. All Rights Reserved. Women should have the option of taking their own test samples for cervical cancer screening, a government ...
Testing for high-risk human papillomaviruses every five years – even with a self-collected sample – is the “preferred screening strategy” for cervical cancer starting at age 30 ...
On Thursday, H.C. Wainwright maintained a positive stance on shares of Zynex Inc. (NASDAQ:ZYXI), reiterating a Buy rating and a $17.00 price target for the company's stock, representing significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback